- Home
- IVP vs KZIA Comparison
IVP vs KZIA Comparison
Compare IVP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- KZIA
- Stock Information
- Founded
- IVP 2020
- KZIA 1994
- Country
- IVP United States
- KZIA Australia
- Employees
- IVP N/A
- KZIA N/A
- Industry
- IVP Diversified Commercial Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- KZIA Health Care
- Exchange
- IVP Nasdaq
- KZIA Nasdaq
- Market Cap
- IVP 6.8M
- KZIA 7.8M
- IPO Year
- IVP 2023
- KZIA 1999
- Fundamental
- Price
- IVP $0.16
- KZIA $1.42
- Analyst Decision
- IVP
- KZIA Strong Buy
- Analyst Count
- IVP 0
- KZIA 1
- Target Price
- IVP N/A
- KZIA $20.00
- AVG Volume (30 Days)
- IVP 5.7M
- KZIA 116.4K
- Earning Date
- IVP 11-13-2024
- KZIA 11-15-2024
- Dividend Yield
- IVP N/A
- KZIA N/A
- EPS Growth
- IVP N/A
- KZIA N/A
- EPS
- IVP N/A
- KZIA N/A
- Revenue
- IVP $17,054,777.00
- KZIA $1,655,324.00
- Revenue This Year
- IVP N/A
- KZIA $806.89
- Revenue Next Year
- IVP N/A
- KZIA N/A
- P/E Ratio
- IVP N/A
- KZIA N/A
- Revenue Growth
- IVP 6.12
- KZIA 248000.00
- 52 Week Low
- IVP $0.14
- KZIA $1.39
- 52 Week High
- IVP $50.00
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- IVP 34.95
- KZIA 20.74
- Support Level
- IVP $0.14
- KZIA $1.42
- Resistance Level
- IVP $0.17
- KZIA $1.89
- Average True Range (ATR)
- IVP 0.02
- KZIA 0.24
- MACD
- IVP -0.00
- KZIA 0.02
- Stochastic Oscillator
- IVP 19.39
- KZIA 1.40
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.